Skip to main content
Bone Biologics Corp logo

Bone Biologics Corp - Investor Relations & Filings

Listed IPO Nov 2022
Ticker · BBLG ISIN · US0980703039 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2025-06-30 Capital/Financing Update
Country US United States of America
Listing US BBLG

About Bone Biologics Corp

https://www.bonebiologics.com/

Bone Biologics Corp. is a medical device company focused on developing therapeutics for bone regeneration. The company's core technology is NELL-1, a proprietary recombinant human protein growth factor designed to enhance orthopedic care. Its lead product candidate, NB1, combines rhNELL-1 with a demineralized bone matrix to function as a bone graft substitute. The primary application for NB1 is in spinal fusion procedures, aiming to provide rapid, specific, and guided bone regeneration. Preclinical studies suggest NELL-1 enhances both the quantity and quality of bone, accelerates healing, and forms bone only in targeted areas without causing inflammation or unwanted bone formation. The company is conducting a pilot clinical study for NB1 in spine fusion patients.

Recent filings

Filing Released Lang Actions
424B4 Filing
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) for a securities offering by Bone Biologics Corporation. It includes information about the shares of common stock, prefunded warrants, Series D and E warrants, pricing, placement agent fees, use of proceeds, risk factors, and other offering details. The document is not a financial report, earnings release, or management discussion, but rather a formal offering document related to capital raising. It is not an announcement of a report but the actual offering prospectus itself. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms and conditions, consistent with a capital raising filing.
2025-06-30 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details a public offering of common stock and warrants, including terms of the offering, pricing, and use of proceeds. It also includes information about the placement agent and related agreements. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy statement, or governance report. It clearly relates to capital raising activities and financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is over 11,000 characters, indicating it is a full report rather than a brief announcement or certification. Confidence is high given the explicit description of the offering and related agreements.
2025-06-30 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about regaining compliance with Nasdaq listing rules, specifically regarding minimum bid price. It does not contain detailed financial statements or comprehensive financial data. The document is short (4099 characters) and primarily serves as a regulatory announcement of an event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-06-26 English
S-1 Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the securities being offered, pricing, placement agent fees, and other offering details. This is not a financial report, earnings release, or management discussion, but a capital raising filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, but the actual registration statement for a securities offering.
2025-06-24 English
S-3 Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Bone Biologics Corporation. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The document includes a prospectus describing the securities to be offered, terms of the offering, risk factors, and other related information. It is not a financial report, earnings release, management discussion, or any other type of report but rather a capital markets filing related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2025-06-24 English
4 Filing
Director's Dealing
2025-06-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.